US$ 28.89
glp 1 agonist heart disease The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Results of cardiovascular outcomes trials
Description
The researchers found that there was a shift toward younger and more females in the exposed population

[DOI] [PubMed] [Google Scholar] 47.Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME

Retrieved from Sharma, G., Mehta, L

PMCID: PMC8572027

From this perspective, receptor-level signaling alone may be insufficient to ensure durable tissue-level outcomes

How is the Middle East and Africa Performing in The GLP-1 Analogues Market
